Retatrutide - Eli Lilly and Company
Alternative Names: GGG Tri-agonist - Eli Lilly and Company; GLP-1/GIP/glucagon tri-agonist - Eli Lilly and Company; LY-3437943Latest Information Update: 28 Jun 2024
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics; Antirheumatics; Cardiovascular therapies; Obesity therapies; Peptides; Sleep disorder therapies
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cardiovascular disorders; Obesity; Osteoarthritis; Sleep apnoea syndrome; Type 2 diabetes mellitus
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Japan (SC, Injection)
- 30 Apr 2024 Phase-III clinical trials in Obesity in Netherlands, Italy, Greece, Belgium (SC) (NCT06383390)
- 30 Apr 2024 Phase-III clinical trials in Obesity in Slovakia, Romania, Israel, Germany, France, Denmark, Czech Republic, Brazil, Austria (SC) (NCT06383390)